tanespimycin

Tanespimycin is a synthetic derivative of the antibiotic geldanamycin and functions as a potent small molecule inhibitor of heat shock protein 90 (HSP90). By binding to HSP90, a molecular chaperone essential for the stability and function of many oncogenic signaling proteins, tanespimycin disrupts multiple cell signaling pathways implicated in tumor growth. This leads to proteasomal degradation of client oncoproteins, induction of apoptosis, and antitumor effects. Tanespimycin was developed primarily for the treatment of various cancers including solid tumors, chronic myelogenous leukemia, and multiple myeloma. It has also been investigated in preclinical models for neurodegenerative diseases due to its ability to induce heat shock proteins and modulate inflammatory responses.

Brand names

Tanespimycin

Other names

tanespimycin